

Claim

1. The use of ET743 in the preparation of a medicament for the treatment of the human body for cancer.
2. A pharmaceutical formulation comprising ET743 for intravenous infusion to treat a human cancer.
3. A method of treating cancer in a human patient which comprises administering ET743.
4. A method of treating advanced and / or metastatic, previously treated cancer in a human patient which comprises administering ET743.
5. A method of treating cancer resistant or refractory to other treatments in a human patient which comprises administering ET743.
6. A method of treating sarcoma in a human patient which comprises administering ET743.
7. A method of treating soft tissue sarcoma in a human patient which comprises administering ET743.

8. A method of treating bone sarcoma in a human patient which comprises administering ET743.
9. A method of treating breast cancer in a human patient which comprises administering ET743.
10. A method of treating cancer in a human patient which comprises administering a dose of ET743 between 1000 and 1500 micrograms per m² of body surface area by intravenous infusion over a period of 24hrs given in multiple cycles of 3 to 4 weeks each with a single administration of the drug on the first day of each cycle.
11. A method of treating cancer in a human patient which comprises administering a dose of ET743 between 1000 and 1650 micrograms per m² of body surface area by intravenous infusion over a period of 3hrs given in multiple cycles of 3 to 4 weeks each with a single administration of the drug on the first day of each cycle.